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for Chinese journals, were searched through to Dec. 31th, 2014. RESULTS: In 2010, 
incidence and mortality of lung cancer in China are 46.08/105 and 37.00/105. DALYs 
(disability adjusted life years) and economic burden of lung cancer are extremely 
high in both Beijing and Shanghai. DALYs of lung cancer are 42219.38 and 91962.18 
in Beijing and Shanghai respectively. And average hospitalization expenditures per 
lung cancer inpatient are ¥38595.00 and ¥50026.65, among which average drug costs 
per inpatient are as high as ¥18139.65(46.97%) and ¥30356.00(60.68%). CONCLUSIONS: 
Lung cancer has made Chinese patients incur great loss in both DALYs and money, 
which is a conspicuous reminder to policy makers to pay more attention to manage-
ment of the raging disease. And early prevention and screening of lung cancer should 
be priorities to slow increasing speed of disease burden.
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OBJECTIVES: Previous real world data from 2013 showed the patterns of care of first-
line NSCLC treatment in the Brazilian supplementary health system: carboplatin 
with pemetrexed (29.7%), bevacizumab containing regimens (20.8%) and oral chemo-
therapy (6%). The same study reported the average cost of management of this 
patients as 19.001,79USD. However, treatment patterns and cost of illness may have 
changed after enacting of a federal law (number 12880/2013) that has established the 
mandatory coverage of oral chemotherapy by the supplementary system. Therefore, 
the aim of this analysis was to evaluate the impact of oral chemotherapy incorpo-
ration in the patterns of care and cost of illness of first-line NSCLC treatment in 
Brazil. METHODS: All metastatic NSCLC patients receiving first-line treatment dur-
ing 2014 were eligible and retrieved from the private market administrative claims 
database (Evidencias- Kantar Health database). Patterns of care were evaluated and 
compared before and after introduction of law 12880/2013. The cost of illness was 
calculated by a bottom-up approach. Exams, fees, and associated drugs reported 
were also considered for costing and values were derived from Tables Simpro and 
CBHPM. Exchange rate used was 1.00USD = 2.20BRL. RESULTS: We studied 110 
patients with first-line NSCLC and found 19 different chemotherapy regimens. We 
observed few changes in the patterns of care: carboplatin with premetrexed is still 
the most used (32,7%), followed now by carboplatin with paclitaxel (19,1%) and 
bevacizumab containing regimen (16,4%). Oral chemotherapy represented 9,1% of 
the regimens. Costs of schemes ranged from 4,963.75USD to 52,374.55USD and the 
calculated average cost of management of one patient is 23,725.76USD. Additionally, 
there was a significant increase in the number PET CT required, from 28% in 2013 to 
48% in 2014. CONCLUSIONS: We observed a low impact of oral chemotherapy incor-
poration in the patterns of care and cost of illness of first-line NSCLC treatment.
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OBJECTIVES: Tyrosine kinase inhibitors (TKIs) represent the standard therapy to 
manage chronic myeloid leukemia (CML) and have resulted in a greatly reduced 
mortality rate. However, up to 40% of patients experience first-line failure, with 
many patients experiencing second-line. This analysis examined healthcare uti-
lization and costs for CML patients that switched to a third-line TKI after having 
failed both first- and second-line TKI therapy. METHODS: Patients with a CML diag-
nosis during 1/1/2010-7/31/2014 and a subsequent claim data for a first-, second-, 
and third-line TKI were identified from the Truven Health MarketScan® Research 
Databases. Inclusion criteria: ≥18 years, continuous enrollment from 3 months 
prior to 6 months post first TKI treatment, no stem cell transplant, and switched to 
second- and third-line TKIs. Healthcare utilization and costs were calculated on a 
per-month basis between (1) initiation of first-line TKI until the switch to second-
line TKI and (2) between second-line TKI initiation until the switch to third-line TKI. 
Nonparamtreic tests were used to test for differences. RESULTS: 137 patients were 
identified (male=532%; female=46.8%; mean age=57.34 years). Average duration of 
first-line TKI therapy was 301.62 days and 269.36.9 days for second-line. Although 
there were large differences among patients, overall, the number of monthly out-
patient visits was higher (p<.05) during second-line therapy (mean=10.51; SD=12.32) 
relative to first-line therapy (mean=9.48; SD=11.37). There were no significant dif-
ferences in monthly emergency room visits or hospitalizations. Healthcare costs 
were higher (p<.05) during second-line therapy than first-line therapy averaging 
$19,764 vs. $13,283 respectively. CONCLUSIONS: Experiencing treatment failure and 
switching to a second- and third-line TKI represents disruption in therapy and was 
associated with substantial healthcare utilization and economic burden for patients 
with CML. This was especially more costly and burdensome for patients who failed 
the second-line TKI therapy, as multiple TKI switches   were associated with a greater 
number of outpatient visits and higher healthcare costs.
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OBJECTIVES: HER2 positive breast cancer management can be costly when a mono-
clonal antibody treatment like trastuzumab is used. This is particularly problematic 
in middle-income countries with a national health insurance system , which have 
mortality, available treatment options, as well as healthcare resource utilization 
and medical costs associated with pancreatic cancer. Critical analyses of study 
quality and data gaps were analyzed at the country level. RESULTS: A total of 328 
studies were identified based on the keywords. Of these, 32 studies met the inclusion 
criteria. Studies indicate that pancreatic cancer has an extremely poor prognosis: 
for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, 
respectively. Pancreatic cancer is the fourth most common cause of cancer-related 
deaths in the United States and the eighth worldwide. More than 50% of patients 
come to clinical attention with metastatic disease, and an additional 30%–40% pre-
sent with locally advanced tumors. Current treatments include surgery and pallia-
tive chemotherapy such as gemicitabine and gemcitabine/erlotinib combination. 
Recently nab-paxclitacel was approved based on a 1.8 month improvement in the 
overall survival. CONCLUSIONS: This systematic review shows that patients with 
pancreatic cancer have a very low survival rate. There is an urgent need for new 
treatments for these patients.
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OBJECTIVES: Cutaneous T-Cell Lymphoma (CTCL) is a rare and serious cancer with 
significant deterioration in patient quality of life. The objective of this research was 
to conduct a systematic review of epidemiology and the burden of CTCL. METHODS: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key findings. 
Extracted study data included: CTCL incidence, complications, mortality, available 
treatment options, as well as healthcare resource utilization and medical costs 
associated with CTCL. Critical analyses of study quality and data gaps were analyzed 
at the country level. RESULTS: A total of 50 studies were identified based on the 
keywords. Of these, 14 studies met the inclusion criteria. Studies indicate that CTCL 
is a group of disorders characterized by localization of neoplastic T lymphocytes 
to the skin. Annual overall incidence of CTCL was 6.4 per million persons between 
1973 and 2002. CTCLs accounted for 71%, with Mycosis fungoides (MF) and Sézary 
syndrome (SS) representing the most common sub-types (54 % of all CTCLs). CTCL 
is associated with a significant symptom burden. Pruritus appears to be one of 
the most prominent and disturbing symptoms. All aspects of QOL are affected in 
CTCL. Two new treatments were approved for CTCL during 2009-2012 (US), however, 
the unmet need remains high. CONCLUSIONS: This systematic review shows that 
patients with CTCL have a very poor prognosis and serious deterioration in quality 
of life. There is an urgent need for new treatments for these patients.
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OBJECTIVES: Data on the association of disability with advanced melanoma are 
limited. This exploratory retrospective cohort study determined rates, timing, 
and costs of STD and LTD in adult patients with newly diagnosed advanced mela-
noma. METHODS: The sample was derived from US administrative claims data-
bases (Truven Health MarketScan®). Disability costs were adjusted to 70% of an 
estimated $30/hour replaced wage. RESULTS: Between April 1, 2011, and December 
31, 2012, 1,052 patients were diagnosed with advanced melanoma. Of these, 109 
patients (mean age, 51.1 years; 92.7% employed full-time) had data eligibility, among 
whom 94 and 95 had STD or LTD eligibility, respectively. Fourteen and 9 patients 
went on STD or LTD, respectively; 2 went on both. Mean time between diagnosis and 
STD or LTD was 115.0 days and 221.8 days, respectively. Mean number of STD and 
LTD days were 67.2 and 105.7, respectively. Seven STD and 6 LTD patients received 
melanoma-specific treatment. Mean time between treatment initiation and STD 
or LTD was 59.4 and 202.5 days, respectively. Mean number of on-treatment days 
(time from treatment initiation until the run-out date, defined by the supply for oral/
subcutaneous products or expected clinical benefit for infused products) was 16.4 
during STD and 25.1 during LTD. Among STD and LTD patients with a return-to-work 
record (n= 14 and n= 5, respectively), mean time to work re-entry was 85.6 and 76.4 
days. Mean costs to employers were similar for STD and LTD ($1,302/patient/month 
vs $1,349/patient/month). CONCLUSIONS: This study provides preliminary esti-
mates of the course of work disability and associated costs in patients with newly 
diagnosed advanced melanoma. Melanoma often affects younger patients thus it 
is important to refine the estimated burden associated with lost work productivity 
in a larger sample with long-term follow up. Future research must also explore the 
impact of recently introduced melanoma therapies on this burden.
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OBJECTIVES: Lung cancer has now become NO.1 disease of all cancers in both inci-
dence and mortality in China. Since lung cancer imposes great disease and eco-
nomic burden on patients in China, lots of studies have investigated national status 
of disease burden of lung cancer. However, few studies pay attention to disease bur-
den of lung cancer in China’s super big cities, such as Beijing &Shanghai. Our study 
aims to review lung cancer’s burden in Beijing and Shanghai to inform policy mak-
ing. METHODS: A comprehensive literature review of disease burden of lung cancer 
in Beijing Shanghai was conducted. “CNKI” and “Wanfang data”, the biggest databases 
A200  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
PCN62
AssessINg the eCoNomIC BurdeN ANd heAlth CAre resourCe 
utIlIzAtIoNs of u.s. medICAre PAtIeNts WIth myeloProlIferAtIve 
NeoPlAsms
Xie L.1, Keshishian A.1, Du J.1, Baser O.2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, The University of Michigan, 
MEF University, Ann Arbor, MI, USA
OBJECTIVES: To examine the economic burden and health care resource utili-
zation of myeloproliferative neoplasms (MPNs) in the U.S. Medicare popula-
tion. METHODS: A retrospective data analysis was performed using the U.S. 
national Medicare claims from January 2008 through December 2012. MPN patients 
were identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis codes 238.4, 238.71, 238.76 and 289.83. The diag-
nosis date was designated as the index date. A comparison cohort without a MPN 
diagnosis was created for patients of the same age, region, gender, index year and 
baseline Charlson Comorbidity Index score. A random index date was chosen for 
the comparison cohort to reduce selection bias. Patients were required to have 
continuous medical and pharmacy benefits 1 year pre- and post-index date. One-
to-one propensity score matching (PSM) was performed to compare follow-up 
health care costs and utilizations between the cohorts, adjusting for demographic 
and clinical characteristics. RESULTS: Eligible patients (N= 17,950) were identified 
for the MPN and comparison cohorts. After 1:1 PSM, a total of 5,546 patients were 
matched from each cohort and baseline characteristics were well-balanced. MPN 
patients had a higher percentage of health care resource utilizations, including 
Medicare carrier (98.6% vs. 65.9%), Durable Medical Equipment (DME; 29.5% vs. 
14.4%), Home Health Agency (HHA; 12.4% vs. 5.0%), outpatient visits (76.6% vs. 
37.4%), inpatient hospitalizations (27.2% vs. 6.8%) and Skilled Nursing Facility (SNF; 
7.5% vs. 2.0%) visits than non-MPN patients. Patients diagnosed with MPNs also 
incurred significantly higher costs, including Medicare carrier ($3,872 vs. $1,283), 
DME ($266 vs. $91), HHA ($639 vs. $250), outpatient ($10,061 vs. $3,204), inpatient 
($5,449 vs. $1,054), pharmacy ($1,069 vs. $713) and total health care costs ($23,060 
vs. $7,076; p< 0.0001). CONCLUSIONS: MPN patients had a higher burden of illness 
compared to non-MPN patients.
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OBJECTIVES: Drug toxicities and adverse events (AE) during cancer treatment pre-
sent a significant economic burden to health systems. Post 2007 there has been no 
systematic review summarizing the costs of AEs related to chemotherapy. Hence, 
the objective of this study is to provide an updated understanding of the cost of 
AEs in cancer treatments in the US. METHODS: A systematic literature search 
was conducted using PubMed. Selection criteria included studies published in 
the English language between January 2008 and October 2013, evaluating the cost 
of following AEs: neutropenia, thrombocytopenia, vomiting, nausea, peripheral 
neuropathy, sepsis, diarrhea and fatigue/asthenia, due to cancer treatment in the 
US. Costs were extracted for case and control cohorts (if available) and the cost 
difference between the cohorts was calculated to provide the additional cost due 
to the AEs. This difference in costs was then adjusted to 2013 USD. RESULTS: A 
total of 893 abstracts were screened, of which 15 unique studies were included. 
The distribution of studies reporting the selected AEs were: neutropenia (n= 5), 
thrombocytopenia (n= 3), vomiting (n= 1), nausea/vomiting (n= 4), peripheral neu-
ropathy (n= 1), sepsis (n= 2), diarrhea (n= 1) and fatigue/asthenia (n= 1). The stud-
ies reported inpatient, outpatient, or total healthcare costs, with different units 
including per patient, per-patient per-year (PPPY), per event or per episode. AE 
costs varied vastly; the per event cost ranged from $213 (outpatient) to $6,000 
(inpatient) while the PPPY cost ranged from $9,800 (outpatient) to $21,000 (total 
healthcare costs). CONCLUSIONS: AEs commonly encountered in cancer treat-
ment remain an expensive problem despite medical advances. In addition to the 
high cost of cancer treatment, the cost of managing AEs adds to the economic 
burden on patients, Payers, and society. This study highlights that the cost of AEs 
associated with cancer treatments are consistently high and consume a large 
portion of healthcare resources.
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OBJECTIVES: Branded biologics will soon begin to face competition from incoming 
biosimilar monoclonal antibodies (mAbs), with many currently in development. 
Given the transition many markets are making towards becoming increasingly cost 
conscious, we sought to investigate how budget holders across the most important 
European markets perceived the incoming oncology biosimilar mAbs. METHODS: 
The research was conducted through in-depth interviews and focus groups with 
budget holders and clinicians across the EU5. RESULTS: All respondents had previ-
ous experience evaluating and making decisions on small molecule biosimilars (e.g. 
filgrastim, EPO). However, there was a lack of experience and knowledge amongst 
EU5 budget holders with biosimilar mAbs and they were unsure how or by whom 
they were going to be educated. The originator product was preferred in all attributes 
tested while costs were cited as the most important driver for encouraging adop-
tion of biosimilar mAbs. Additionally, budget holders across the EU5 were adamant 
about encouraging automatic substitution (albeit, initially only for new patients), of 
the originator until enough experience was built up (at least 12 months, 24 months 
likely). Respondents also suggested that key institutions or regions will make deci-
sions early on while other less resourced centres/regions will adopt their decision. 
Conversely, clinicians were apprehensive of biosimilar mAbs and anticipate resisting 
to contemplate The question how innovative technologies can be financed is there 
even more pronounced. We estimated the direct medical costs of breast cancer treat-
ment in Iran in the period of 21/03/2011-20/03/2014 and examined the fraction of 
total costs related to trastuzumab use. METHODS: A retrospective claims database 
analysis was performed using data from the Iran Social Security Organization, a 
health insurer which covers approximately 50% of the Iranian population. Data min-
ing techniques helped to identify patients and determine resource use in the three 
stages of breast cancer (early, loco-recurrence and advanced). Using a healthcare 
perspective, absolute and relative costs of various medical services associated with 
treatment of HER2-positive breast cancer among Iranian women in both public and 
private healthcare systems were calculated. RESULTS: The patient population com-
prised 1295 women (mean (SD) age: 45.6 (10.3) years) and mean follow-up was 739 
days (range:21-1072). Average costs of drugs and chemotherapy in early, loco-recur-
rence and advanced stages were € 2,707 (range:€ 98-€ 23,680), € 2,751 (€ 31-€ 23,420) and 
€ 13,030 (€ 115-€ 45,833), respectively. Average costs of radiotherapy and diagnostic 
tests were € 2,138 (€ 5-€ 49,534), € 516 (€ 2-€ 9,064) and € 507 (€ 6-€ 17,125). Trastuzumab 
accounted for the largest share of total costs (58%), followed by paraclinical services 
(12%), radiotherapy (10%), and other drugs and chemotherapy (9%). CONCLUSIONS: 
Trastuzumab is an expensive drug may which require a substantial share of avail-
able budgets. These cost estimates can be included in cost-effectiveness analyses 
to determine if these costs are justified from a health economic view. Moreover, if 
relevant data are available, data mining techniques can support real-world cost-
effectiveness analyses in middle-income countries and thereby help to optimize 
reimbursement decisions.
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OBJECTIVES: An estimated 17 million people in the US have Barrett’s Esophagus 
(BE), a precursor to esophageal cancer (EAC). The low probability of progressing 
to EAC (less than 2%) and the inability of standard histopathology to risk stratify 
BE patients have resulted in inefficient surveillance protocols and calls for effec-
tive innovation to identify higher risk patients. A newly-developed biomarker 
test can risk stratify BE patients for progression to high grade dysplasia (HGD) 
and EAC. The test stratifies patients into high, medium and low risk categories, 
giving providers actionable information for BE endoscopy surveillance frequency 
and treatment decisions such as radiofrequency ablation (RFA). This study evalu-
ates the cost-effectiveness of this new biomarker test compared with the current 
standard of care (SOC) surveillance and treatment of BE. METHODS: Decision 
analysis with Markov modeling and cohort simulation were used to model treat-
ment costs and outcomes from a health plan perspective. Costs were derived from 
Geisinger Health Plan claims data and quality-adjusted life-years (QALYs) from 
the medical literature. The model includes realistic assumptions for physician 
adherence to SOC for patients in each risk category. RESULTS: Preliminary results 
of a 5 year model of using the new biomarker test compared to SOC include an 
incremental cost-effectiveness ratio of $75,804 in U.S. 2012 dollars. Cumulative 
endoscopies in the biomarker test arm were 6.23% greater than with SOC and 
there were 73.3% fewer cumulative RFAs under SOC than with the biomarker 
test. Compared with SOC, the number of patients in the HGD, EAC, and death 
states in the biomarker test arm were 52.5%, 60.9% and 9.83% fewer, respec-
tively. CONCLUSIONS: Using this new biomarker test to risk stratify BE patients 
is cost-effective at the $100,000 threshold and, due to more effective surveillance 
and treatment protocols, results in fewer patients transitioning to HGD, EAC, and 
death.
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OBJECTIVES: To evaluate the health care resource utilization and economic burden 
of non-Hodgkin’s lymphoma (NHL) in the U.S. Medicare population. METHODS: 
NHL patients were identified (International Classification of Diseases, 9th Revision, 
Clinical Modification [ICD-9-CM] diagnosis codes 200.xx and 202.xx) using national 
U.S. Medicare claims from January 1, 2009 through December 31, 2011. The first diag-
nosis date was designated as the index date for the NHL cohort. Control patients of the 
same age, region, gender and index year were identified and matched to case patients 
based on baseline Charlson Comorbidity Index (CCI) scores, and were assigned a ran-
domly chosen index date to minimize selection bias. Patients were required to have 
continuous medical and pharmacy benefits 1 year pre- and post-index date. Study 
outcomes, including health care costs and utilizations, were compared between the 
disease and comparison cohorts using 1:1 propensity score matching (PSM). RESULTS: 
A total of 20,254 patients were included in the NHL and comparison cohorts. After 
1:1 PSM, 4,705 patients were matched from each cohort and baseline characteristics 
were balanced. Patients diagnosed with NHL were more likely to utilize health care 
resources including Medicare carrier (99.0% vs. 70.5%), Durable Medical Equipment 
(DME, 28.1% vs. 17.7%), Home Health Agency (HHA, 11.4% vs. 4.8%), outpatient visits 
(80.2% vs. 41.0%), inpatient stays (25.7% vs. 7.4%) and Skilled Nursing Facility (SNF, 
4.8% vs. 1.7%) and hospice admissions (0.9% vs. 0.3%). Patients diagnosed with NHL 
also incurred higher Medicare carrier ($10,603 vs. $1,522), DME ($264 vs. $120), HHA 
($531 vs. $270), outpatient ($30,013 vs. $4,268), inpatient ($5,762 vs. $1,167), SNF ($875 
vs. $307), hospice ($197 vs. $67), pharmacy ($1,050 vs. $785) and total costs ($49,296 
vs. $8,507; p< 0.005). CONCLUSIONS: The economic burden and health care resource 
utilizations were significantly higher for patients diagnosed with NHL compared to 
patients without NHL.
